Zeaxanthin and Lutein: study protocols
14 study groups took Zeaxanthin together with Lutein. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Zeaxanthin
14 study groups in 8 studies say how much Zeaxanthin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 64% of 14 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mcg or less | 1 |
| 100 mcg to 250 mcg | 1 |
| 250 mcg to 500 mcg | 0 |
| 500 mcg to 1 mg | 2 |
| 1 mg to 2.5 mg | 9 |
| 2.5 mg to 5 mg | 0 |
| over 5 mg | 1 |
Dose per serving from research: Lutein
14 study groups in 8 studies say how much Lutein participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg, 86% of 14 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg to 10 mg | 12 |
| 10 mg to 25 mg | 2 |
Commonly used together
10 of 14 study groups took Zeaxanthin and Lutein with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Omega-3 Fatty Acids | 8 |
| Docosahexaenoic Acid | 5 |
14 study groups
| Study | ||||
|---|---|---|---|---|
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 2 mg | 10 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 2 mg | 10 mg | 1789 days | — |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 2 mg | 10 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 2 mg | 10 mg | 1789 days | — |
| Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration 2015 · lutein (10 mg) + zeaxanthin (10 mg) · Adults aged over 50 with clinically diagnosed early age-related macular degeneration | 10 mg | 10 mg | 2 years | 28 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 2 mg | 10 mg | 12 weeks | 96 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 2 mg | 10 mg | 24 weeks | 40 |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · low-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 96 mcg | 6 mg | 6 weeks | 29 |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · high-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 192 mcg | 12 mg | 6 weeks | 26 |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 1 mg | 10 mg | 1 year | — |